Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders (QoQ) (2013 - 2023)
Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders (QoQ) (2013 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Galmed Pharmaceuticals | 2.31 Mn | -9.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 100.00% |
| Sep 30, 2022 | -147.11% |
| Mar 31, 2021 | 100.03% |
| Dec 31, 2020 | -200.08% |
| Sep 30, 2020 | 7,886.26% |
| Jun 30, 2020 | -2,100.00% |
| Mar 31, 2020 | -99.69% |
| Dec 31, 2019 | 758,836.36% |
| Sep 30, 2019 | 31.25% |
| Jun 30, 2019 | 55.56% |
| Mar 31, 2019 | -100.97% |
| Dec 31, 2018 | 358.10% |
| Sep 30, 2018 | 11,657.14% |
| Jun 30, 2018 | -124.14% |
| Mar 31, 2018 | -99.20% |
| Dec 31, 2017 | 30.10% |
| Sep 30, 2017 | 4.05% |
| Jun 30, 2017 | -15.24% |
| Mar 31, 2017 | -34.19% |
| Dec 31, 2016 | 33.24% |